Navigation Links
Global Breast Health & Wellness Center Expands Use of Cryoablation for Treatment of Early Stage Breast Cancer
Date:1/30/2017

Global Breast Health & Wellness Center, founded by Dr. April Speed, announced it has expanded its cryoablation treatment of fibroadenoma to include early stage breast cancer with the Visica® 2 Treatment System. Developed by Sanarus Technologies, the Visica 2 Treatment System is a cryoablation device that uses extreme cold liquid nitrogen (cryo) to destroy tissue (ablation). The device destroys the tumor by freezing and damaging the adjacent vasculature that fuels tumor growth.

Dr. April L. Speed is board-certified by the American College of Surgeons and is a member of the American Society of Breast Surgeons, the Society of Surgical Oncology and the American Society of Clinical Oncology (ASCO). Dr. Speed was recognized by her peers and awarded the ASCO National Diversity in Oncology Award in 2009.

Cryoablation—also referred to as tumor freezing—is a minimally invasive procedure done under ultrasound guidance in the doctor’s office or radiology suite. After injection of local anesthesia, a thin probe is inserted through the skin directly into the tumor. Liquid nitrogen is pumped into the probe to form an “ice ball” around the lesion. Freezing destroys the tumor cells, which are then reabsorbed by the body over time. The procedure can be done in less than an hour with most patients reporting minimal discomfort and a resumption of normal activity right away. Little, if any, visible scarring occurs. Because no breast tissue is removed during the procedure, the natural shape of the breast is maintained.

”I’ve been providing cryoablation for the treatment of fibroadenomas since 2015 and have obtained very good results” said Dr. Speed. “Those results coupled with the publication of the National Cancer Institute Z1072 Trial have truly encouraged me to expand my practice to offer cryoablation for early stage breast cancer tumors.”

In a 5-year multicenter study funded by the National Cancer Institute and sponsored by the Alliance for Clinical Trials in Oncology, cryoablation with the Visica 2 Treatment System was shown to be 100% effective for complete ablation of invasive ductal breast cancer tumors <1.0 cm. The Visica 2 Treatment System was the exclusive device used in the Z1072 study and showed cryoablation to be effective in 92% of the targeted lesions. Results from this breast cancer study (ACOSOG Z1072), which included a 5-year follow-up, were published in the Annals of Surgical Oncology.

Dr. Speed further explained that “In November 2016, I opened my new state of the art facility located in Buckhead to provide Greater Atlanta with a comprehensive, 100% dedicated, breast surgery practice. Cryoablation is one of our primary treatment options for our patients because it provides an opportunity for women to have cutting edge therapy with dignity and detail performed in a serene, patient-centered environment. It also gives women the benefit of a minimally invasive procedure with little to no scarring, downtime, or discomfort.”

Dr. Speed recently discussed cryoablation and other breast cancer related topics on Atlanta Business RadioX. She discussed the technology of cryoablation, who would qualify as a patient, and why she has chosen to offer cryoablation for the treatment of early stage breast cancer lesions. She has also been featured on CentricTV.

Cryoablation with the Visica 2 Treatment System is a nonsurgical option for patients that have been diagnosed early stage breast tumor that is less than 4 cm in diameter, is visible on sonogram and has been confirmed with a biopsy.

About Global Breast Health & Wellness Center
Dr. Speed serves on several boards, the Susan G. Komen for the Cure Greater Atlanta Affiliate, and the Georgia Perimeter College. She's a highly sought-after speaker, author, consultant and lecturer on breast cancer and breast health. Dr. Speed has recently embarked upon an exciting venture of private practice in two convenient locations, Buckhead and Conyers, and welcomes all of her previous patients and new patients alike to continue to be a part of this amazing journey of transformation from your Breast Health to your Best Health?. Let's treat it, beat it, move on!? To contact Dr. Speed go http://www.draprilspeed.com or call 678.210.2846

About Sanarus Technologies
In 2001, the Visica® 2 Treatment System was the first available for cryoablation of fibroadenomas. Since then, our system has been used to successfully treat thousands of patients. The Visica 2 Treatment System is FDA-cleared for the ablation of cancerous or malignant tissue and benign tumors. At Sanarus, we develop innovative solutions for the nonsurgical treatment of breast tumors. We are headquartered in Pleasanton, CA, and all of our products are manufactured in the USA. Find out more at http://www.sanarus.com

Read the full story at http://www.prweb.com/releases/2017/01/prweb14019995.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. BlueCloud by HealthCarePoint Establishes Global Advisory Board
2. Statement from UN Foundation President & CEO Kathy Calvin on New Restrictions of U.S. Foreign Assistance to Limit Women’s Access to Health Care Globally
3. Gensuite Gives Back: Global Gensuite Team Raises Nearly $15,000 for Charities around the World
4. New DrugDev Educational Webinar Shows Pharma How to Put the “Informed" Back Into Patient Consent for Global Clinical Studies with Groundbreaking Mobile Solution
5. Clinical Supplies Management Begins Global Expansion Through Acquisition of Theorem Clinical Research – Clinical Supplies in Frankfurt, Germany
6. GeBBS Healthcare Solutions Named Key Player in Global Medical Billing Market
7. Adaptive Sound Technology, Inc. Expands Global Sales with Launch of Sound Machines Into Asia
8. Mizuho OSI and Trilux Medical join forces for the first time at MEDICA 2016 proving their commitment to providing global innovative operating room solutions.
9. Trefz Family Gift Creates First Global Health Endowed Chair in Connecticut
10. 2016 Global CME Impact Award Submission Deadline Extended
11. AvePoint and CIPL Assess Global Preparation for EU General Data Protection Regulation with First-Ever Readiness Benchmark Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is in ... red these days. According to recent estimates, 75 – 80% of the medical ... Some studies point to Electronic Health Records (EHR) with automated features designed to ...
(Date:6/25/2017)... CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music video ... above footage and sound in the timeline and write in the lyrics to any song. ... flying back out. Each line of the text can be added modularly for optimal control. ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation ... significant harm to people with all chronic conditions, including mental illnesses, while increasing ... place the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... -- The Cincinnati location of Diplomat ... DPLO), has been awarded a Top Workplaces 2017 ... are based on an employee survey administered by WorkplaceDynamics, LLC, ... The survey measures several aspects of workplace culture, including alignment, ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology: